Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IDOR 11342831

Next Previous
Drug Profile

IDOR 11342831

Alternative Names: IDO-090; IDOR-1134-2831

Latest Information Update: 01 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Idorsia Pharmaceuticals
  • Class Bacterial vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Clostridium difficile infections

Most Recent Events

  • 01 Jul 2024 Phase-I clinical trials in Clostridium difficile infections in Germany (Prevention, In volunteers) (Parenteral) (CTIS2023-506407-26-00)
  • 19 Sep 2023 Preclinical trials in Clostridium difficile infections in Switzerland (Parenteral), prior to September 2023 (Idorsia Pharmaceuticals pipeline, September 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top